Dissemination (Meeting Coverage)

High-dose melphalan conditioning confers survival benefits in patients with extramedullary and non-extramedullary multiple myeloma.

African Americans benefit from targeted multiple myeloma interventions.

AI detects lung cancer better than humans do.

While patients with hepatocellular carcinoma largely felt independent, their caregivers reported burdens related to appointment logistics and emotional support.

Researchers at the 2024 ASCO Annual Meeting studied the rapid titration of venetoclax for chronic lymphocytic leukemia and mantle cell lymphoma.

Patients with multiple myeloma who were admitted for gastrointestinal bleeding had higher costs and mortality than those without multiple myeloma.

Ultrasensitive Circulating Tumor DNA improves clinical sensitivity of minimal residual disease in early stage non-small cell lung cancer.

HCC survival time is predicted by albumin-bilirubin grade, microvascular invasion, and distant metastases.

Social determinants of health create barriers that delay access to expensive oral anti-myeloma drugs for people with newly diagnosed multiple myeloma.

AI and ML advances chronic lymphocytic leukemia therapies.

The following is a summary of “Association between treatment (tx) response and PFS and OS in R/R...

The following is a summary of “Evaluating CR as a surrogate endpoint for PFS in R/R chronic...

The following is a summary of “Survival outcomes with adjuvant immunotherapy after hepatic...

The following is a summary of “Identification of a predictive phosphoproteomic signature of...

The following is a summary of “Identification of molecular subtypes for integrated multi-omics...

The following is a summary of “Atezolizumab + bevacizumab versus lenvatinib as first-line systemic...

Researchers at the 2024 ASCO Annual Meeting found racial and ethnic disparities in palliative care use among patients with advanced hepatocellular carcinoma.

Fixed duration ibrutinib plus venetoclax benefited survival outcomes in patients with high-risk CLL/SLL over more than 5 years of follow-up.

Investigators examined the changes in mortality rates due to COVID-19, influenza, and pneumonia in patients with MM.

The treatment landscape for non-small cell lung cancer has significantly evolved with the advent of targeted therapies.